- Home
- LSB vs MRKR Comparison
LSB vs MRKR Comparison
Compare LSB & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- MRKR
- Stock Information
- Founded
- LSB 2002
- MRKR N/A
- Country
- LSB China
- MRKR United States
- Employees
- LSB N/A
- MRKR N/A
- Industry
- LSB
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- MRKR Health Care
- Exchange
- LSB NYSE
- MRKR Nasdaq
- Market Cap
- LSB 41.2M
- MRKR 35.8M
- IPO Year
- LSB N/A
- MRKR N/A
- Fundamental
- Price
- LSB $2.71
- MRKR $3.50
- Analyst Decision
- LSB
- MRKR Strong Buy
- Analyst Count
- LSB 0
- MRKR 1
- Target Price
- LSB N/A
- MRKR $19.00
- AVG Volume (30 Days)
- LSB 82.0K
- MRKR 34.9K
- Earning Date
- LSB 11-22-2024
- MRKR 11-22-2024
- Dividend Yield
- LSB N/A
- MRKR N/A
- EPS Growth
- LSB N/A
- MRKR N/A
- EPS
- LSB N/A
- MRKR N/A
- Revenue
- LSB $79,415,311.00
- MRKR $3,727,435.00
- Revenue This Year
- LSB $39.33
- MRKR $35.94
- Revenue Next Year
- LSB $75.61
- MRKR N/A
- P/E Ratio
- LSB N/A
- MRKR N/A
- Revenue Growth
- LSB N/A
- MRKR N/A
- 52 Week Low
- LSB $1.88
- MRKR $2.44
- 52 Week High
- LSB $11.20
- MRKR $6.16
- Technical
- Relative Strength Index (RSI)
- LSB 43.57
- MRKR 46.47
- Support Level
- LSB $1.91
- MRKR $3.52
- Resistance Level
- LSB $3.23
- MRKR $3.90
- Average True Range (ATR)
- LSB 0.55
- MRKR 0.40
- MACD
- LSB 0.16
- MRKR -0.08
- Stochastic Oscillator
- LSB 53.57
- MRKR 0.00
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.